In close cooperation with the Szentágothai Research Center (University of Pécs), iBioScience Ltd. provides the Hungarian scientific community with the most modern next-generation sequencing technology and background expertise. . At the Research Center, the company supports the application of next-generation sequencing in research, technology development and diagnostics with instrumentation and specialists.
’Genomics holds an enormous opportunity because both rare diseases and cancer are closely linked to changes in the genome.
We expect great interest from Hungarian patients and their families who would take part in this pioneering project.
We plan to sequence 10,000 whole human genomes, determine the order of the building blocks of the hereditary material, that is, assess the participants’ genetic status.
The project will in fact focus on patients with rare diseases and their families, as well as cancer patients, but we also plan to conduct population genomics studies.
Our goal is a voluntary, consensual and ethical program that benefits patients. We are confident that we can facilitate scientific discoveries that will be able to kick-start a Hungarian genomics industry.
The management of the University and the Szentágothai Research Center attracted Hungarian professionals from abroad who set up, run and developed such institutes and research groups at renowned European biotechnology organizations.
An important milestone was to win two European Union and Hungarian joint funding which have enabled us not only to acquire and manage personnel but also to operate the required world-class research infrastructure.
The most important will be to make personalized, precision medicine even more widespread in Hungary which will yield results not only in research, but also in everyday diagnostics.’
Dr. Gyenesei Attila
Head of the Bioinformatics Research Group (Szentágothai Research Center)
